UK Steel Industry Faces Uncertainty Amid 2025 US Tariffs
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
UK Steel Industry Faces Uncertainty Amid 2025 US Tariffs
In 2025, the British steel industry suffered major setbacks after the United States infringed a 25 percent tariff on steel and aluminum imports. This future event alarmed British manufacturers and policymakers because it might heavily impact exports…
Ultra-Fast Charging Batteries From StoreDot will Begin Mass Production In 2025
In 2025, StoreDot, a leading battery technology company, announced the mass production of their revolutionary silicon-based batteries, which will forever change the world of electric vehicles (EVs). Their new battery innovation that stores 70% of…
EIA Cuts Oil Demand Forecast as U.S.-China Tariff War Sends Prices Crashing
April 11, twenty twenty-five Amid rising trade tensions and new rounds of tariffs, the United States (U.S.) Energy Information Administration (EIA) on Thursday lowered its predictions for worldwide oil demand growth as oil prices fell more than 4…
Germany Rejects Revival of Nord Stream Pipelines Amid 2025 Energy Shift
Emphasizing that such conversations are wrong among continuous Russian aggression in Ukraine, Germany's departing Economy and Energy Minister, Robert Habeck, strongly objected in March 2025 to discussions about restoring the Nord Stream gas…
OpenAI Empowers Next-Gen Innovation in 2025 with Advanced GPT Models and Investments
In April 2025, OpenAI achieved substantial milestones in both funding and strategic partnerships, highlighting its growing influence in the artificial intelligence (AI) sector. A whopping $40 billion in funding was secured by OpenAI, which was valued…
Indu Tyagi Ketan
Chief Strategy Officer
Latest News
Ultra-Fast Charging Batteries From StoreDot will Begin Mass Production In 2025
EIA Cuts Oil Demand Forecast as U.S.-China Tariff War Sends Prices Crashing
Germany Rejects Revival of Nord Stream Pipelines Amid 2025 Energy Shift
OpenAI Empowers Next-Gen Innovation in 2025 with Advanced GPT Models and Investments
